The purpose of this report is to announce the availability and describe the salient characteristics of a strain of Pseudomonas aeruginosa for use in quality control testing of aminoglycosides and other antipseudomonal antimicrobial agents. Antimicrobial therapy with aminoglycoside antibiotics requires regular monitoring of levels of the agent in serum to ensure dosage levels adequate to attain microbial inhibition and to maintain levels below concentrations known to result in nephrotoxicity, neurotoxicity, or ototoxicity. For mild to moderate infections, desired peak and trough levels for gentamicin and tobramycin are 4 to 8 and 1 to 2 ,ug/ml, respectively, while the levels for amikacin are 20 to 25 and 5 to 8 ,ug/ml, respectively. Because of the need for precise dosing, laboratory reports of MICs for clinical isolates from patients receiving aminoglycoside therapy must be reported in modified twofold-dilution schemes or in small arithmetic increments (1, 2, 5) . For quality control of determinations of in vitro MICs of aminoglycosides for P. aeruginosa clinical isolates, the National Committee for Clinical Laboratory Standards recommends use of P. aeruginosa ATCC 27853 (3). The expected MICs for this organism fall in the lower end of the clinically useful range for the aminoglycosides and are 1.0 to 4.0, 0.5 to 2.0, and 2.0 to 8.0 ,ug/ml for gentamicin, tobramycin, and amikacin, respectively.
Eight years ago, after screening numerous P. aeruginosa clinical isolates, we selected one which might improve quality control testing of aminoglycosides by having midrange MICs. The isolate, then designated SPR-88, was used in several studies of P. aeruginosa versus the aminoglycosides to evaluate precision and accuracy of midrange MICs for several commercial antimicrobial susceptibility testing systems (5-7). For the past 6 years, we have utilized this isolate, now held in the American Type Culture Collection as P. aeruginosa ATCC 49189, for routine in vitro quality control testing in our laboratory for a number of antipseudomonal antimicrobial agents, including gentamicin, tobramycin, and amikacin. The expected MICs of these last agents are 5.0 to 9.0, 2.0 to 3.0, and 6.0 to 10.0 ,ug/ml, respectively. These values, especially for the more commonly used gentamicin and tobramycin, more accurately represent actual therapeutic levels of these agents, are removed from the endpoint of most dilution schemes and thus occur on scale as discrete integers, and have remained * Corresponding author. stable and reproducible through several years of daily use of the drugs.
The organism has been maintained in stock culture at -70°C in 1.5 ml of defibrinated sheep blood in the stock culture collection of the Clinical Microbiology Laboratory at St. Paul-Ramsey Medical Center. This stock culture was used to make annual working cultures which were stored in similar fashion and from which fresh plates were prepared weekly by introduction of a hot inoculating loop for daily subculture for quality control of P. aeruginosa susceptibility testing. Figure 1 illustrates the results of quality control tests for gentamicin, tobramycin, and amikacin with P. aeruginosa ATCC 49189 conducted in our laboratory from 1 January 1983 to 1 November 1988. All testing was performed on an MIC 2000 Automatic Inoculator (Dynatech Laboratories, Inc., Alexandria, Va.) with panels manufactured by us on an MIC 2000 96-channel dispenser with 0.1 ml of antibiotic per well as described previously (4). Aminoglycosides were arrayed in small arithmetic increments differing by 1 ,ug/ml and ranging from 1 to 16 ,ug/ml for gentamicin and tobramycin and differing by 2 ,ug/ml and ranging from 2 to 32 ,ug/ml for amikacin. Other agents were arrayed in twofold-dilution schemes with endpoints determined by the active spectrum of each agent. A total of 16 different lots of approximately 420 panels each were manufactured during the study period. Each panel was sealed with tape and frozen at -70°C until use. As had been previously demonstrated (4-7), statistical evaluation of repeated MIC determinations for P. aeruginosa ATCC 49189 versus gentamicin, tobramycin, and amikacin shows a high degree of single-lot precision and remarkable accuracy in occurrence about the modal value, especially considering the small-increment format. For gentamicin, the mean value for 1,525 tests (Fig. 1A) was 7 .20, the standard deviation was 0.83, and the coefficient of variation was 11.51. For the 1,373 tobramycin tests (Fig.  1B) , the same statistical parameters were 2.04, 0.23, and 11.21, respectively. For the 1,605 amikacin tests (Fig. 1C) , these parameters were 8.31, 1.47, and 17.67, respectively.
The disparity in total numbers of tests for the three agents is due to selective data suppression for brief intervals during the study period.
Quality control data for P. aeruginosa ATCC 49189 versus various other antipseudomonal agents are portrayed in Table A 1. As evidenced by the total number of tests, several agents, including cefotaxime, mezlocillin, and piperacillin, have been tested consistently, while several others, including carbenicillin, ceftazidime, and ciprofloxacin, were introduced later in the study. Cefoperazone and moxalactam were deleted from test panels during the study period. Ceftazidime and piperacillin MICs fell consistently below 1-and 2-,ug/ml values, respectively, and thus were off scale in a normal integer or twofold-dilution scheme. For the remaining agents, expected MICs for P. aeruginosa ATCC 49189 occurred on scale, closely approximated those for P. aeruginosa ATCC 27853, and were acceptable for quality control purposes.
